Earlier we performed dendritic cell-based immunotherapy in a preclinical tumor model as well as in patients with mesothelioma. These studies showed that administration of whole tumor cell lysate-pulsed dendritic cells is feasible and that it can induce distinct immune responses and antitumor responses. However, some hurdles need to be overcome for improving clinical efficacy. Alleviation of the tumor-induced immune suppression could improve the efficacy of immunotherapy. In this study, 3 to 5 injections of tumor lysate-loaded monocytederived mature dendritic cells were administered to five patients after pemetrexed-cisplatin or pemetrexed-carboplatin treatment and five patients after induction chemotherapy followed by pleurectomy/decortication. Simultaneously, a metronomic dose of cyclophosphamide (CTX) was administered to these patients to investigate its potency to overcome immunosuppression by regulatory T cells (Treg). We showed that 1-week of CTX significantly reduced the mean Treg percentage of total CD4 cells in peripheral blood, but an elevated Treg percentage initially was only found in a minority of patients. Furthermore, we demonstrated the safety and feasibility of this combination therapy in mesothelioma patients and found sustained tumor control.
At a glance commentary
Earlier we performed dendritic cell-based immunotherapy in a preclinical tumor model as well as in patients with mesothelioma. These studies showed that administration of whole tumor cell lysate-pulsed dendritic cells is feasible and that it can induce distinct immune responses and antitumor responses. However, some hurdles need to be overcome for improving clinical efficacy. Alleviation of the tumor-induced immune suppression could improve the efficacy of immunotherapy. In this study, 3 to 5 injections of tumor lysate-loaded monocytederived mature dendritic cells were administered to five patients after pemetrexed-cisplatin or pemetrexed-carboplatin treatment and five patients after induction chemotherapy followed by pleurectomy/decortication. Simultaneously, a metronomic dose of cyclophosphamide (CTX) was administered to these patients to investigate its potency to overcome immunosuppression by regulatory T cells (Treg). We showed that 1-week of CTX significantly reduced the mean Treg percentage of total CD4 cells in peripheral blood, but an elevated Treg percentage initially was only found in a minority of patients. Furthermore, we demonstrated the safety and feasibility of this combination therapy in mesothelioma patients and found sustained tumor control.
Online data supplement
This article has an online data supplement, which is accessible from this issue's table of content online at www.atsjournals.org
Introduction
Malignant pleural mesothelioma (MPM) is a highly lethal neoplasm with limited treatment options. Despite aggressive treatments with combinations of surgery, chemotherapy, and radiotherapy, it is almost inevitably accompanied with recurrences. Remarkably, however, long-term survivors do occur either with or without any treatment (1, 2) . This may be explained by germline mutations, in which patients with BAP1 mutations recently were found to have an overall 7-fold increased long-term survival (3) . Also, the role of the immune system in mesothelioma has provided new insights, which begin to explain the differences in the complex behavior of individual tumors and also uncover new possibilities for treatment (4) .
Earlier we performed a phase I clinical trial using active immunotherapy in ten mesothelioma patients, who were treated with chemotherapy followed by three vaccinations of autologous tumor lysate-pulsed monocyte-derived dendritic cells (DC) (5) . Results showed that these vaccines were well tolerated without systemic toxicity, and radiographic tumor responses were established. We were also able to detect distinct immune and cytotoxic T lymphocyte antitumor activity in the peripheral blood of these patients.
It is now well recognized that the efficacy of immunotherapy is influenced by the immunosuppressive environment created by the tumor (6) . The presence of this immunosuppressive environment hampers attempts at harnessing the potency of the immune system. An increasing number of immunosuppressive factors and cells are reported in malignant diseases. We, among others, have established that regulatory T-cells (Tregs) play a major role in mesothelioma by contributing to an impaired T-cell function (7, 8) .
Clinical studies have shown that low-dose cyclophosphamide (CTX) induces beneficial immunomodulatory effects in the context of active or adoptive immunotherapy by reducing the number of Tregs and their functionality (9, 10) . In our murine model of mesothelioma we found that prolonged (metronomic) lowdose CTX augmented the anti-tumor effects of DC vaccines and increased survival via a reduction of the number of Tregs (11) .
In the present study, we investigated whether these preclinical findings could be confirmed in patients. Ten patients with MPM who had previously been treated with chemotherapy or chemotherapy and debulking surgery were treated with CTX combined with DC-based immunotherapy as a consolidation/adjuvant treatment. The aim was to establish a reduction in the number of circulating Tregs by CTX and to determine the safety of immune therapy in these patients. We found that CTX combined with DC-immunotherapy was feasible and safe and that the number of Tregs in peripheral blood was reduced by a single cycle of CTX.
Although in this report we will focus on the clinical results, the relevant immunological data will be presented. Significant increases in immune responsiveness were established, and overall survival was encouraging, with seven of the ten patients surviving ≥24 months. Some of the results of the present study have been previously reported in the form of an abstract (12) .
Materials and Methods

Study design
The study was approved by the institutional ethical committee of the Erasmus MC Response was assessed according to modified RECIST criteria (13) .
Patients with either partial response or stable disease were evaluated for study treatment with DC-based immunotherapy. In case of progressive disease after chemotherapy, patients were excluded from participation and treated according to the clinicians' and patient's decision. It is general practice in our reference center to consider patients for a pleurectomy/decortication (P/D) only after completion of chemotherapy, in case of persistent complaints, e.g. dyspnea, related to tumor load. P/D is only performed in patients who are fit for operation and in whom a macroscopic debulking is considered feasible according to published guidelines.
DC-based immunotherapy in combination with low dose CTX was planned 8 to 10 weeks after completion of the most recent cytoreductive therapy, i.e. either chemotherapy or surgery (figure 1). During treatment, blood and serum samples were taken from each participant at regular intervals. The blood samples were tested for immunological responses, liver function and renal function. In addition, the serum samples were screened for the development of auto-immunity. Overall survival was defined as survival after date of diagnosis. Final survival data was gathered in August 2015.
The study endpoints were (1) the reduction of regulatory T cells in the blood of patients after CTX, and (2), the safety and efficacy of the combination therapy consisting of DC vaccinations and CTX in MPM patients. Patients were treated with 2 times 50 mg tablet/day of CTX (Endoxan; Baxter B.V., Utrecht, The Netherlands) starting one week before vaccination to the day of every vaccination (followed by a week interval (figure 1)). The patients were asked to take the medication 2 hours after breakfast and dinner and to increase their fluid intake by drinking extra water or other non-caffeinated beverages during the day. Urine of patients was routinely checked for signs of hematuria. 
Patient eligibility
Results
Patients
Clinical response evaluation
Radiographic responses performed after the third vaccination are shown in table 2. Of the 5 non-surgical patients, 4 had SD and 1 had CR after DC therapy. In 3 of the surgically treated patients, the disease could not be evaluated, because surgery led to a macroscopic CR. However, 2 surgical patients presented with new lesions after DC therapy and therefore had PD. Therefore, in total, disease control (no remaining evaluable disease, CR, PR and SD) was achieved in 8 out of 10 patients. In addition, table 2 shows the overall survival of the patients with a follow up time of 6 years. Seven of the 10 patients had a survival of ≥ 24 months (table 2 and figure 2 ). In August 2015, 2 patients were still alive, 1 of whom was in complete remission 66 months after diagnosis, and in the other the disease was very slowly progressive 50 months after diagnosis. 
Safety and toxicity
None of the 10 patients withdrew from the study. There were no logistic problems or practical problems in the preparation process, so all vaccinations were given as planned. The safety and toxicity of the combination of a low dose CTX (orally) and tumor lysate-pulsed DCs injected intradermally and intravenously in patients with MPM were assessed. No related grade >3 toxicities were found in any of the patients. Table 3 presents a summary of the main adverse events not related to tumor progression. Injection of DCs was well tolerated without systemic toxicity, except for transient fatigue and low-grade fever on the day of the DC injection.
These symptoms normalized after one day. After DC injection, a local skin reaction in the form of erythema without induration was seen in more than half of the subjects. Subsequent vaccinations (second and third) gave a quicker and increased induration and erythema in all patients, suggesting that some form of immunity was induced. None of the study participants developed any clinical evidence of autoimmunity. One patient developed a cardiomyopathy 18 months after DC vaccination. This was deemed to be related to the previous cisplatin treatment.
Treg numbers
After 
Immune responses
In all patients, a comparison of pre-first-vaccine and post-third-vaccine serum samples showed a significant increase of antibodies reactive to the model antigen vaccinations were completed (data not shown). Three months after the third vaccination , KLH responses were evidently present in the 6 patients in whom it could be determined. This proves that a successful immune reaction was induced by the DC vaccinations ( Figure 5 ).
Skin DTH testing
The DTH skin test was performed two weeks after the third vaccination and was evaluable in all patients. There were no skin reactions to saline as the negative The role of surgery in mesothelioma is under debate (17, 18) . This is due to disease recurrences after surgery. Therefore, an effective adjuvant treatment is of the utmost importance. Animal models have shown that resection of an established primary tumor reduced the tumor-associated immune suppressive environment (19) . This theoretically supports the combination of surgery and immunotherapeutic strategies. Our data confirm that this combination is feasible and should be studied further.
The addition of CTX resulted in a decrease in the percentage Tregs of total blood CD4 cells in most patients during CTX treatment, independent of the initial Treg percentage. This reduction was also found in previous studies with a similar metronomic low-dose schedule (20, 21) . By contrast, single dose and twice-aweek dosing of CTX did not show an effect on Treg numbers (22, 23) . Whether the decrease in Treg percentage caused an increased immune response cannot be concluded from these data, as no control group was included. The results found in this study are similar to our earlier murine experiments with DC immunotherapy and CTX (11) . In that study, we did find survival to be increased when Treg levels were reduced.
The fact that we found normal peripheral blood Treg percentages in a significant number of patients may be a reflection of patient selection, since we selected patients who were non-progressing or responding to chemotherapy. It cannot be determined from our data whether Treg levels do play a role in these patients. It cannot be excluded that in the patients with normal Treg other immunosuppressive mechanisms are more prominent, such as M2 tumorassociated macrophages (TAMs) or myeloid derived suppressor cells (MSDCs).
This finding could thus be of importance for personalizing immunotherapy. In this small study, no relations were established between initial Treg percentage or decrease in Tregs and radiologic response and overall survival. This can be due to the small sample size, but it is also possible that the number of circulating
Tregs is not indicative of the Treg numbers within the tumor.
The DTH skin test proves that an effective immune response to KLH can be induced by DC vaccination, but this test was not positive for tumor lysate and/or tumor lysate loaded DCs in all patients. Although the number of patients is too small to draw any definite conclusion, the 2 patients that experienced progressive disease after DC vaccination and had the shortest survival had shown a negative skin test for both tumor lysate and tumor lysate loaded DCs.
Therefore, the skin test should be evaluated in a larger cohort of patients as a marker for the outcome of DC vaccination therapy.
Serum KLH responses were seen in all patients, but only after completion of the third vaccination. In our previous trial, responses were already present after the first vaccination(5). This difference is likely due to the suppressive effect of CTX on B cells (24) . This is subject for further study.
Another subject for further research is the impact of the immunosuppressive environment created by the tumor. This has now been shown to be both complex and subject to dynamic changes over time. This study has some limitations. First, the number of patients included in this study is rather limited due to the considerable costs and labor involved in the production of the DC vaccination therapy. Furthermore, our study group was a heterogeneous group with different subhistologies, different stages of disease and different initial therapeutic approaches (e.g. surgical and non-surgical cases).
Also, due to lack of randomization, the possibility of selection bias was present.
While this did not seem to have an effect on the primary outcome of our study (Treg reduction and feasibility), it could have had an effect on the survival data.
Second, while radiographic CT scanning was performed, no PET scans were done. An earlier trial with immunotherapy showed a decrease in tumor FDG uptake (28, 29) . Although the immune responses generated could also increase FDG-activity via the influx of immune cells, as has been suggested recently(30),
PET-imaging could have yielded additional information.
Third, in the non-surgery group the autologous tumor lysate used for antigen loading of dendritic cells originated from treatment-naïve patients, while in the surgery group the tumor lysate was prepared from resected material derived from patients who had received chemotherapy as an induction to their surgery, which means that the tumor had already been treated. Three patients in the surgical group showed a prolonged survival, but selection bias should be considered. In addition, the 2 other surgical patients showed PD. The numbers of our study are too small to draw conclusions on this subject, but this will be addressed in future studies.
Fourth, the efficacy of CTX on the suppression of Tregs was assessed by measuring the Treg values in peripheral blood. While this way of studying Tregs is the most convenient method for the patient, Treg levels in peripheral blood might not be representative for the Treg density at the tumor site (31, 32) .
However, in mesothelioma, repeat biopsies are only feasible in selected patients.
Fifth, although unlikely, we cannot rule out the possibility that leukapheresis has a temporary influence on the Treg numbers. Baseline values of Tregs were obtained at screening, before leukapheresis, while the Treg samples after CTX treatment were obtained after leukapheresis. To our knowledge, the impact of leukapheresis on Treg count is unknown. In 4 patients treated with DC vaccination, a total blood count including leucocyte differentiation was available at the 2 time points at which Tregs were measured, and these showed no change in leucocyte count or shift in leucocyte differentiation. Also, CTX was able to reduce Treg counts in previous studies without leukapheresis attributing the Treg decrease to CTX alone (9, 21) . 
Conclusions of the study
Short
Dendritic cell culture
We used our previously described method to generate clinical-grade mature dendritic cells in conformity with Good Manufacturing Practice (GMP)
guidelines (5). In brief, concentrated 120 to 150 ml leukocyte fractions were generated through a 4-h restricted peripheral blood leukapheresis, processing on average 9L of blood (COBE Spectra Apheresis System, Gambro BCT, Zaventem, Belgium). Peripheral blood mononuclear cells were then enriched using counterflow centrifugal elutriation (Elutra, Gambro BCT, Zaventem, Belgium) as described by Berger et al.(34) . In 60% of the cases, the percentages of contaminating granulocytes in the enriched monocyte fractions after counter-flow centrifugal elutriation were below 10%. A density gradient centrifugation was routinely performed on all samples to remove the granulocytes before starting the culturing process. In this way, the percentages of granulocytes at the start of the procedure were always below 8% for all preparations. Monocytes were resuspended at a concentration of 5x10 6 
Delayed type hypersensitivity skin test
To assess the patient's immunocompetence, DTH skin testing was performed one week before the apheresis by means of intradermal application of tetanus toxoid (positive control) and a physiological salt solution (negative control) on the ventral surface of the patient's forearm. If this did not result in a response to tetanus that could be related to the effects of chemotherapy, apheresis was postponed and the skin DTH test was repeated two weeks later. If the second test was also negative the patient was excluded from participation in the study. A DTH skin test was also performed two weeks after the third vaccination; it was further completed with autologous tumor lysate (10 µg), KLH (5 µg), tumor lysate loaded DC with or without KLH (both 5x10 6 cells). DTH responses were evaluated after 48 h.
Immune response assessment against KLH
Serum samples were collected into SST serum separation tubes (BD biosciences) before, during, and in the lifelong clinical follow-up of the patients. After allowing the serum 30 min to clot, tubes were centrifuged 10 min at 1000 x g. Serum was collected, aliquoted and stored at -80 °C until use. Humoral responses to KLH were measured in the serum of patients by ELISA. Microtiter plates (96 wells)
were coated overnight at 4 °C with 25 µg/ml KLH in PBS per well. After blocking the plates with 1% powdered milk in PBS, different concentrations of patient serum (range, 1 in 100 to 1 in 500,000) were added for 1 h at room temperature.
After extensive washing, specific anti-human IgG or anti-human IgM conjugated with horseradish peroxidase were allowed to bind for 1 h at room temperature.
Peroxidase activity was revealed with the use of 3,3'5,5-tetramethyl-benzidine (TMB) as substrate, and absorbance was measured in a microtiter plate reader (VersaMax, Molecular Devices, Sunnyvale, CA, USA).
Treg analysis
Blood samples obtained before the treatment protocol and at the first vaccination (after induction cyclophosphamide) were analyzed. Tregs were defined as CD3+, CD4+, CD25+, FoxP3+, and CD127-. Before immune staining, the cells were stained for viability using LIVE/DEAD Fixable Aqua Dead Cell Stain (Invitrogen life technologies) in PBS. Subsequently the cells were washed in FACS buffer
